The FDA has approved five new indications for atorvastatin (Lipitor) in patients with cardiovascular disease, according to its manufacturer.
The company said in a press release Wednesday that atorvastatin has now been approved for reducing the risks for nonfatal myocardial infarctions, fatal and nonfatal strokes, certain types of heart surgery, hospitalization for heart failure, and angina in patients with established coronary heart disease. This is the first statin to be approved for reducing the risk for hospitalization because of heart failure, according to the press release.
The company said that the approval was based on results from the Treating to New Targets (TNT) and the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trials.
http://today.reuters.com/news/articleinvesting.aspx?view=CN&storyID=2007-03-07T170531Z_01_N07229356_RTRIDST_0_PFIZER-LIPITOR-UPDATE-1.XML&rpc=66&type=qcna
No comments:
Post a Comment